Phase 3, multicenter, multinational, open-label study to evaluate the safety and efficacy of alfimeprase in subjects with occluded central venous access devices (SONOMA-3).

Trial Profile

Phase 3, multicenter, multinational, open-label study to evaluate the safety and efficacy of alfimeprase in subjects with occluded central venous access devices (SONOMA-3).

Completed
Phase of Trial: Phase III

Latest Information Update: 02 Jun 2011

At a glance

  • Drugs Alfimeprase (Primary)
  • Indications Catheter thrombosis
  • Focus Adverse reactions
  • Acronyms SONOMA-3
  • Sponsors ARCA biopharma Inc
  • Most Recent Events

    • 12 May 2009 Actual initiation date changed from Feb 2006 to Jan 2006 as reported by ClinicalTrials.gov.
    • 12 May 2009 ClinicalTrials.gov has reported company added as trial sponsor, affiliate and additional lead trial investigator identified.
    • 17 Mar 2008 Results have been reported. Nuvelo's chairman has stated that "[w]e did not see the robust increase in activity or dose resonse expected", and as such, Nuvelo has ended its alfimeprase clinical development program.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top